Discontinued — last reported Q3 '22
S&P Global Acquisitions increased by 108.3% to $25.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 733.3%, from $3.00M to $25.00M. Over 2 years (FY 2021 to FY 2024), Acquisitions shows an upward trend with a 75.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $9.00M | $80.00M | -$295.00M | $20.00M | $33.00M | $272.00M | $14.00M | $7.00M | $3.00M | $1.00M | $260.00M | $3.00M | $41.00M | $13.00M | $12.00M | $25.00M |
| QoQ Change | — | +800.0% | +788.9% | -468.8% | +106.8% | +65.0% | +724.2% | -94.9% | -50.0% | -57.1% | -66.7% | >999% | -98.8% | >999% | -68.3% | -7.7% | +108.3% |
| YoY Change | — | — | — | — | >999% | +266.7% | +192.2% | -30.0% | -78.8% | — | -99.6% | >999% | -57.1% | >999% | >999% | -95.4% | +733.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.